87
Participants
Start Date
May 14, 2021
Primary Completion Date
April 10, 2023
Study Completion Date
December 31, 2025
LOXO-305
Administered orally.
Affiliated Hospital of Hebei University, Baoding
Beijing Cancer hospital, Beijing
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Shanghai East Hospital, Shanghai
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing
The First Affiliated Hospital of Soochow University, Suzhou
Wannan Medical College Yijishan Hospital, Wuhu
Institute of hematology&blood disease hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
Xiangya Hospital Central South University, Changsha
Hunan Cancer Hospital, Changsha
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi
Southern Medical University Nanfang Hospital, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Hainan General Hospital, Haikou
Sichuan Cancer Hospital, Chengdu
Xi'an International Medical Center Hospital, Xi'an
Xinjiang Medical University Cancer Hospital - Urumqi, Ürümqi
Xingtai People's Hospital, Xingtai
Collaborators (1)
Loxo Oncology, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY